Turkish Journal of Internal Medicine

Yazarlar: İ̇brahim AKDAĞ, Alparslan ERSOY

Konular:Genel ve Dahili Tıp

DOI:10.46310/tjim.766086

Anahtar Kelimeler:Chronic kidney disease,Methotrexate,Psoriatic arthritis,Rheumatoid arthritis,Pancytopenia

Özet: Methotrexate (MTX) is widely used in the treatment of both rheumatoid arthritis (RA) and psoriatic arthritis (PA) with a side effect of pancytopenia. However, very few cases of severe pancytopenia caused by low-dose MTX therapy have been described in chronic kidney disease. Pancytopenia occurred after using a single dose of MTX in three patients with chronic kidney dysfunction. While one patient died due to sepsis and multiple organ failure, the others recovered. The severity of MTX-inducedpancytopenia in our cases was likely related to the underlyingkidney disease. These cases suggest that uremic patients may develop severe fatal bone marrow toxicity even with a single dose of MTX. Therefore, close blood count monitoring after MTX treatment in this population would be beneficial.

---